Q4 2024 Hansa Biopharma AB Earnings Call Transcript

Author's Avatar
Feb 06, 2025

Feb 06, 2025 / 01:00PM GMT
Operator

Good day and welcome to the Hansa Biopharma year end and fourth quarter, 2024 report. (Operator Instructions) I would now like to turn the conference over to Soeren Tulstrup, President and CEO. Please go ahead.

Soeren Tulstrup - Hansa Biopharma AB - President, Chief Executive Officer

Thank you, Operator. Good afternoon, good morning and welcome to the Hansa Biopharma conference call to review the full year and Q4 results for 2024. I'm Soeren Tulstrup, President and CEO; of Hansa Biopharma. Joining me today is Evan Ballantyne, Chief Financial Officer and Hitto Kaufmann Chief R&D officer.

Please allow me to draw your attention to the fact that they will be making forward-looking statements during this presentation, and you should therefore apply appropriate caution.

Please turn to slide 3 and an overview today's agenda. Today we'll discuss the progress we made during the fourth quarter and review the full year 2024 performance. The presentation should take roughly 15 to 20 minutes after which there will be an opportunity to ask questions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot